Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jay Barth sold 20,000 shares of the stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $16.80, for a total transaction of $336,000.00. Following the completion of the sale, the insider now directly owns 105,409 shares in the company, valued at $1,770,871.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Jay Barth also recently made the following trade(s):

  • On Tuesday, January 2nd, Jay Barth sold 5,000 shares of Amicus Therapeutics stock. The stock was sold at an average price of $14.71, for a total transaction of $73,550.00.
  • On Friday, December 1st, Jay Barth sold 5,000 shares of Amicus Therapeutics stock. The stock was sold at an average price of $13.59, for a total transaction of $67,950.00.

Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at $16.07 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. The company has a market cap of $2,650.00, a PE ratio of -8.72 and a beta of 1.72. Amicus Therapeutics, Inc. has a one year low of $5.07 and a one year high of $17.40.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The company had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative return on equity of 132.40% and a negative net margin of 1,026.91%. Amicus Therapeutics’s revenue was up 419.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.33) earnings per share. sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FOLD. Schwab Charles Investment Management Inc. boosted its stake in shares of Amicus Therapeutics by 5.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 592,934 shares of the biopharmaceutical company’s stock valued at $5,971,000 after purchasing an additional 29,983 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Amicus Therapeutics by 1.6% during the second quarter. Legal & General Group Plc now owns 55,411 shares of the biopharmaceutical company’s stock valued at $558,000 after purchasing an additional 852 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Amicus Therapeutics by 16.3% during the second quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock valued at $2,073,000 after purchasing an additional 28,800 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Amicus Therapeutics by 3.2% during the second quarter. Teachers Advisors LLC now owns 261,545 shares of the biopharmaceutical company’s stock valued at $2,634,000 after purchasing an additional 8,046 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Amicus Therapeutics by 12.0% during the second quarter. TIAA CREF Investment Management LLC now owns 487,751 shares of the biopharmaceutical company’s stock valued at $4,912,000 after purchasing an additional 52,136 shares in the last quarter.

FOLD has been the topic of a number of research analyst reports. Bank of America upped their target price on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Leerink Swann restated a “buy” rating and issued a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Robert W. Baird restated an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, Chardan Capital restated a “buy” rating and issued a $18.50 target price (up from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Amicus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $18.31.

COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics, Inc. (FOLD) Insider Jay Barth Sells 20,000 Shares” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/01/26/amicus-therapeutics-inc-fold-insider-jay-barth-sells-20000-shares.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.